BHC
Bausch Health Companies Inc.
+0.03 (+0.62%)5.73USD418K成交股數2.1B市值–本益比(近四季)0.2股價營收比+12.7%營收年增(近四季)2026-10-28下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 2.9B+26% | 2.5B-1% | 2.7B+7% | 2.5B+5% | 2.3B+5% | 2.6B+14% | 2.5B+16% | 2.4B+24% | 2.2B | 2.2B | 2.2B | 1.9B |
| 營業成本 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利率 | – | – | – | – | – | – | – | – | – | – | – | – |
| 研發費用 | 173M | 163M | 166M | 159M | 143M | 163M | 146M | 156M | 151M | 153M | 156M | 143M |
| 銷售管理費用 | 907M | 861M | 795M | 894M | 867M | 820M | 850M | 832M | 794M | 715M | 711M | 725M |
| 營業利益 | 740M+168% | −950M-270% | 619M+95% | 444M+14% | 276M-2% | 558M+3886% | 318M-23% | 389M+122% | 281M | 14.0M | 412M | 175M |
| 營業利益率 | 25.9% | -37.6% | 23.1% | 17.5% | 12.2% | 21.8% | 12.7% | 16.2% | 13.1% | 0.6% | 19.0% | 9.0% |
| 稅後淨利 | 258M-545% | −1.4B-1630% | 179M-311% | 148M+1380% | −58.0M-9% | 93.0M-125% | −85.0M-427% | 10.0M-105% | −64.0M | −378M | 26.0M | −201M |
| 淨利率 | 9.0% | -56.4% | 6.7% | 5.8% | -2.6% | 3.6% | -3.4% | 0.4% | -3.0% | -16.9% | 1.2% | -10.3% |
| 稀釋 EPS | 0.68-525% | -3.82-1692% | 0.48-309% | 0.40+1233% | -0.16-6% | 0.24-123% | -0.23-429% | 0.03-105% | -0.17 | -1.03 | 0.07 | -0.55 |
| 稀釋股數 | 378M | 373M | 376M | 373M | 370M | 368M | 368M | 370M | 367M | 365M | 367M | 363M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 1.8B | 1.3B | 1.3B | 1.7B | 1.1B | 1.2B | 719M | 595M | 733M | 760M | 579M | 518M |
| 應收帳款 | 2.3B | 2.2B | 2.4B | 2.2B | 2.1B | 2.1B | 2.1B | 2.1B | 2.0B | 1.9B | 1.7B | 1.7B |
| 存貨 | 1.6B | 1.6B | 1.6B | 1.7B | 1.6B | 1.6B | 1.7B | 1.6B | 1.6B | 1.3B | 1.2B | 1.2B |
| 總資產 | 24.8B | 24.5B | 26.8B | 27.3B | 26.4B | 26.5B | 26.5B | 26.5B | 26.9B | 27.1B | 25.5B | 25.4B |
| 有息負債 | 19.9B | 19.9B | 20.5B | 20.9B | 21.2B | 18.9B | 21.1B | 21.2B | 21.5B | 21.9B | 20.1B | 20.2B |
| 總負債 | 25.6B | 25.6B | 26.5B | 27.1B | 26.7B | 26.8B | 26.8B | 26.7B | 27.1B | 27.3B | 25.2B | 25.3B |
| 股東權益 | −1.8B | −2.1B | −565M | −764M | −1.2B | −1.3B | −1.2B | −1.2B | −1.1B | −1.2B | −663M | −800M |
| 負債比 | 103.2% | 104.4% | 98.7% | 99.5% | 100.9% | 101.2% | 100.9% | 100.9% | 100.6% | 100.9% | 98.9% | 99.4% |
| 淨現金(現金 − 有息負債) | −18.1B | −18.6B | −19.2B | −19.1B | −20.1B | −17.8B | −20.3B | −20.6B | −20.8B | −21.1B | −19.5B | −19.7B |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | 230M | – | – | 211M0% | – | – | – | 211M | – | – | 154M |
| 資本支出 | – | 109M | – | – | 115M | – | – | – | 82.0M | – | – | 47.0M |
| 自由現金流 | – | 121M | – | – | 96.0M-26% | – | – | – | 129M | – | – | 107M |
| 折舊攤銷 | – | 295M | – | – | 305M | – | – | – | 320M | – | – | 319M |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | 4.8% | – | – | 4.2% | – | – | – | 6.0% | – | – | 5.5% |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
業務分部2025 年度 · 7.7B
| Bausch Lomb | 5.1B | 66.4% | +6.5% |
|---|---|---|---|
| International Rx | 1.1B | 14.7% | +1.9% |
| Diversified | 937M | 12.2% | -1.4% |
| Solta Medical | 518M | 6.7% | +17.7% |
| Salix 小計 | 2.6B | 33.5% | +10.5% |
地區2025 年度 · 7.1B
| United Statesand Puerto Rico | 6.1B | 86.7% | +6.4% |
|---|---|---|---|
| 韓國 | 234M | 3.3% | +60.3% |
| RU | 198M | 2.8% | +23.0% |
| 日本 | 192M | 2.7% | +2.1% |
| 德國 | 176M | 2.5% | +10.7% |
| 英國 | 141M | 2.0% | +4.4% |
| 其他國家 小計 | 1.2B | 16.3% | +6.5% |
| 中國 小計 | 493M | 7.0% | -0.6% |
| 加拿大 小計 | 417M | 5.9% | +3.7% |
| PL 小計 | 382M | 5.4% | +9.1% |
| 墨西哥 小計 | 278M | 3.9% | -11.7% |
| 法國 小計 | 249M | 3.5% | +8.3% |
產品／服務2025 年度 · 20.6B
| 產品 | 10.2B | 49.4% | +6.7% |
|---|---|---|---|
| Pharmaceutical Products | 4.7B | 23.1% | +8.0% |
| Device Products | 2.4B | 11.9% | +8.9% |
| Overthe Counter Products | 2.0B | 9.8% | +5.5% |
| Brandedand Other Generic Products | 962M | 4.7% | -1.7% |
| Product And Service Other | 110M | 0.5% | +2.8% |
| Other Revenues | 110M | 0.5% | +2.8% |
| Price Appreciation Credit | 18.0M | 0.1% | 0.0% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 10.3B | +6.7% | 157M | 1.5% | 0.42 | 1.0B |
| FY2024 | 9.6B | +9.9% | −46.0M | -0.5% | -0.13 | 1.3B |
| FY2023 | 8.8B | +7.8% | −592M | -6.8% | -1.62 | 817M |
| FY2022 | 8.1B | -3.7% | −225M | -2.8% | -0.62 | −946M |
| FY2021 | 8.4B | +5.1% | −948M | -11.2% | -2.64 | 1.2B |
| FY2020 | 8.0B | -6.7% | −560M | -7.0% | -1.58 | 809M |
| FY2019 | 8.6B | +2.6% | −1.8B | -20.8% | -5.08 | 1.2B |
| FY2018 | 8.4B | – | −4.1B | -49.5% | -11.81 | 1.3B |